☰

Samuel R. Denmeade, M.D. - Publications

Affiliations: 
Johns Hopkins University, Baltimore, MD 
Area:
Pharmacology, Biochemistry, Oncology
Website:
https://www.hopkinsmedicine.org/pharmacology_molecular_sciences/faculty/bios/denmeade.html
Tree Info Similar researchers PubMed Report error

246 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Kumar R, Mendonca J, Shetty A, Yang Y, Owoyemi O, Wilson L, Boyapati K, Topiwala D, Thomas N, Nguyen H, Luo J, Paller CJ, Denmeade S, Carducci MA, Kachhap SK. CRM1 regulates androgen receptor stability and impacts DNA repair pathways in prostate cancer, independent of the androgen receptor. Biorxiv : the Preprint Server For Biology. PMID 38405771 DOI: 10.1101/2024.02.13.579966  0.483
2024 Wise DR, Pachynski RK, Denmeade SR, Aggarwal RR, Deng J, Febles VA, Balar AV, Economides MP, Loomis C, Selvaraj S, Haas M, Kagey MH, Newman W, Baum J, Troxel AB, et al. A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Prostate Cancer and Prostatic Diseases. PMID 38341461 DOI: 10.1038/s41391-024-00798-z  0.477
2024 Denmeade SR. Resolute Progress Down a Long and Winding Road Leads to the Promised Land of Prostate-Specific Membrane Antigen-Based Therapies for Prostate Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2302310. PMID 38181307 DOI: 10.1200/JCO.23.02310  0.499
2024 Markowski MC, Taplin ME, Aggarwal R, Sena LA, Wang H, Qi H, Lalji A, Sinibaldi V, Carducci MA, Paller CJ, Marshall CH, Eisenberger MA, Sanin DE, Yegnasubramanian S, Gomes-Alexandre C, ... ... Denmeade SR, et al. Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial. Nature Communications. 15: 14. PMID 38167882 DOI: 10.1038/s41467-023-44514-2  0.342
2023 Mori JO, Elhussin I, Brennen WN, Graham MK, Lotan TL, Yates CC, De Marzo AM, Denmeade SR, Yegnasubramanian S, Nelson WG, Denis GV, Platz EA, Meeker AK, Heaphy CM. Prognostic and therapeutic potential of senescent stromal fibroblasts in prostate cancer. Nature Reviews. Urology. PMID 37907729 DOI: 10.1038/s41585-023-00827-x  0.788
2023 Isaacs JT, Dalrymple SL, Antony L, Marc Rosen D, Coleman IM, Nelson PS, Kostova M, Murray IA, Perdew GH, Denmeade SR, Akinboye ES, Brennen WN. Third generation quinoline-3-carboxamide transcriptional disrupter of HDAC4, HIF-1α, and MEF-2 signaling for metastatic castration-resistant prostate cancer. The Prostate. PMID 37559436 DOI: 10.1002/pros.24606  0.746
2023 Wang A, Lazo M, Lu J, Couper DJ, Prizment AE, Vitolins MZ, Denmeade SR, Joshu CE, Platz EA. Liver fibrosis scores and prostate cancer risk and mortality in the Atherosclerosis Risk in Communities (ARIC) Study. Cancer Prevention Research (Philadelphia, Pa.). PMID 37339266 DOI: 10.1158/1940-6207.CAPR-23-0168  0.427
2023 Sena LA, Wang H, Denmeade SR. First, do no harm: The unclear benefit of lifelong castration for patients with metastatic prostate cancer. The Prostate. PMID 37244750 DOI: 10.1002/pros.24582  0.524
2023 Denmeade SR, Sena LA, Wang H, Antonarakis ES, Markowski MC. Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer. The Oncologist. PMID 37027449 DOI: 10.1093/oncolo/oyad055  0.396
2023 Shenderov E, De Marzo AM, Lotan TL, Wang H, Chan S, Lim SJ, Ji H, Allaf ME, Chapman C, Moore PA, Chen F, Sorg K, White AM, Church SE, Hudson B, ... ... Denmeade SR, et al. Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial. Nature Medicine. PMID 37012549 DOI: 10.1038/s41591-023-02284-w  0.438
2022 Sena LA, Wang T, Wang H, Markowski MC, Antonarakis ES, Denmeade SR. Updated analyses for RESTORE cohort C: A trial of bipolar androgen therapy for patients with newly castration-resistant prostate cancer. European Journal of Cancer (Oxford, England : 1990). 181: 23-25. PMID 36628897 DOI: 10.1016/j.ejca.2022.12.001  0.463
2022 Kumar R, Sena LA, Denmeade SR, Kachhap S. The testosterone paradox of advanced prostate cancer: mechanistic insights and clinical implications. Nature Reviews. Urology. PMID 36543976 DOI: 10.1038/s41585-022-00686-y  0.549
2022 Tran PT, Lowe K, Tsai HL, Song DY, Hung AY, Hearn JWD, Miller S, Proudfoot JA, Deek MP, Phillips R, Lotan T, Paller CJ, Marshall CH, Markowski M, Dipasquale S, ... Denmeade S, et al. Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2201662. PMID 36367998 DOI: 10.1200/JCO.22.01662  0.506
2022 Sena LA, Kumar R, Sanin DE, Thompson EA, Rosen DM, Dalrymple SL, Antony L, Yang Y, Gomes-Alexandre C, Hicks JL, Jones T, Bowers KA, Eskra JN, Meyers J, Gupta A, ... ... Denmeade SR, et al. Prostate cancer androgen receptor activity dictates efficacy of bipolar androgen therapy through MYC. The Journal of Clinical Investigation. PMID 36194476 DOI: 10.1172/JCI162396  0.789
2022 Denmeade S, Lim SJ, Isaaccson Velho P, Wang H. PSA provocation by bipolar androgen therapy may predict duration of response to first-line androgen deprivation: Updated results from the BATMAN study. The Prostate. PMID 35938545 DOI: 10.1002/pros.24426  0.446
2022 Markowski MC, Wang H, De Marzo AM, Schweizer MT, Antonarakis ES, Denmeade SR. Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss. European Urology Open Science. 41: 112-115. PMID 35677016 DOI: 10.1016/j.euros.2022.05.006  0.496
2022 Denmeade S, Antonarakis ES, Markowski MC. Bipolar androgen therapy (BAT): A patient's guide. The Prostate. PMID 35357024 DOI: 10.1002/pros.24328  0.514
2021 Isaacs JT, Brennen WN, Christensen SB, Denmeade SR. Mipsagargin: The Beginning-Not the End-of Thapsigargin Prodrug-Based Cancer Therapeutics. Molecules (Basel, Switzerland). 26. PMID 34946547 DOI: 10.3390/molecules26247469  0.756
2021 Kumar R, Mendonca J, Owoyemi O, Boyapati K, Thomas N, Kanacharoen S, Coffey M, Topiwala D, Gomes C, Ozbek B, Jones T, Rosen M, Dong L, Wiens S, Brennen WN, ... ... Denmeade SR, et al. Supraphysiological testosterone induces ferroptosis and activates immune pathways through nucleophagy in prostate cancer. Cancer Research. PMID 34645612 DOI: 10.1158/0008-5472.CAN-20-3607  0.733
2021 Markowski MC, Kachhap S, De Marzo AM, Sena LA, Luo J, Denmeade SR, Antonarakis ES. Molecular and Clinical Characterization of Patients With Metastatic Castration Resistant Prostate Cancer Achieving Deep Responses to Bipolar Androgen Therapy. Clinical Genitourinary Cancer. PMID 34538582 DOI: 10.1016/j.clgc.2021.08.001  0.448
2021 Sena LA, Denmeade SR, Antonarakis ES. Targeting the spectrum of immune checkpoints in prostate cancer. Expert Review of Clinical Pharmacology. 1-14. PMID 34263692 DOI: 10.1080/17512433.2021.1949287  0.542
2021 Sena LA, Denmeade SR. Fatty acid synthesis in prostate cancer: vulnerability or epiphenomenon? Cancer Research. PMID 34145040 DOI: 10.1158/0008-5472.CAN-21-1392  0.518
2021 Zhu Y, Dalrymple SL, Coleman I, Zheng SL, Xu J, Hooper JE, Antonarakis ES, De Marzo AM, Meeker AK, Nelson PS, Isaacs WB, Denmeade SR, Luo J, Brennen WN, Isaacs JT. Correction: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. Oncogene. PMID 33958727 DOI: 10.1038/s41388-021-01805-6  0.736
2021 Marshall CH, Tunacao J, Danda V, Tsai HL, Barber J, Gawande R, Weiss C, Denmeade SR, Joshu C. Reversing the effects of androgen deprivation therapy in men with metastatic castration resistant prostate cancer. Bju International. PMID 33765326 DOI: 10.1111/bju.15408  0.482
2021 Denmeade SR, Wang H, Agarwal N, Smith DC, Schweizer MT, Stein MN, Assikis V, Twardowski PW, Flaig TW, Szmulewitz RZ, Holzbeierlein JM, Hauke RJ, Sonpavde G, Garcia JA, Hussain A, et al. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2002759. PMID 33617303 DOI: 10.1200/JCO.20.02759  0.484
2021 Zhu Y, Dalrymple SL, Coleman I, Zheng SL, Xu J, Hooper JE, Antonarakis ES, De Marzo AM, Meeker AK, Nelson PS, Isaacs WB, Denmeade SR, Luo J, Brennen WN, Isaacs JT. Correction to: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. Oncogene. PMID 33564077 DOI: 10.1038/s41388-021-01640-9  0.736
2020 Sena LA, Wang H, Lim ScM SJ, Rifkind I, Ngomba N, Isaacs JT, Luo J, Pratz C, Sinibaldi V, Carducci MA, Paller CJ, Eisenberger MA, Markowski MC, Antonarakis ES, Denmeade SR. Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy. European Journal of Cancer (Oxford, England : 1990). 144: 302-309. PMID 33383350 DOI: 10.1016/j.ejca.2020.11.043  0.457
2020 Brennen WN, J Thorek DL, Jiang W, Krueger TE, Antony L, Denmeade SR, Isaacs JT. Overcoming stromal barriers to immuno-oncological responses via fibroblast activation protein-targeted therapy. Immunotherapy. PMID 33148078 DOI: 10.2217/imt-2020-0066  0.73
2020 Zhu Y, Dalrymple SL, Coleman I, Zheng SL, Xu J, Hooper JE, Antonarakis ES, De Marzo AM, Meeker AK, Nelson PS, Isaacs WB, Denmeade SR, Luo J, Brennen WN, Isaacs JT. Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. Oncogene. PMID 32989253 DOI: 10.1038/s41388-020-01479-6  0.694
2020 Rogers OC, Antony L, Levy O, Joshi N, Simons BW, Dalrymple S, Rosen M, Pickering A, Lan H, Kuang H, Ranganath SH, Zheng L, Karp JM, Howard SP, Denmeade SR, et al. Microparticle Encapsulation of a Prostate-Targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-Resistant Prostate Cancer. Molecular Cancer Therapeutics. PMID 32943549 DOI: 10.1158/1535-7163.Mct-20-0227  0.819
2020 Deek MP, Taparra K, Dao D, Chan L, Phillips R, Gao RW, Kwon ED, Deville C, Song DY, Greco S, Carducci MA, Eisenberger M, DeWeese TL, Denmeade S, Pienta K, et al. Patterns of Recurrence and Modes of Progression Following Metastasis Directed Therapy in Oligometastatic Castration Sensitive Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics. PMID 32798608 DOI: 10.1016/J.Ijrobp.2020.08.030  0.53
2020 Markowski MC, Wang H, Sullivan R, Rifkind I, Sinibaldi V, Schweizer MT, Teply BA, Ngomba N, Fu W, Carducci MA, Paller CJ, Marshall CH, Eisenberger MA, Luo J, Antonarakis ES, ... Denmeade SR, et al. A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. European Urology. PMID 32624280 DOI: 10.1016/J.Eururo.2020.06.042  0.591
2020 Deek MP, Taparra K, Phillips R, Velho PI, Gao RW, Deville C, Song DY, Greco S, Carducci M, Eisenberger M, DeWeese TL, Denmeade S, Pienta K, Paller CJ, Antonarakis ES, et al. Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer. European Urology Oncology. PMID 32536574 DOI: 10.1016/J.Euo.2020.05.004  0.499
2020 Hasan H, Deek MP, Phillips R, Hobbs RF, Malek R, Radwan N, Kiess AP, Dipasquale S, Huang J, Caldwell T, Leitzel J, Wendler D, Wang H, Thompson E, Powell J, ... ... Denmeade S, et al. A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS). Bmc Cancer. 20: 492. PMID 32487038 DOI: 10.1186/S12885-020-07000-2  0.522
2020 Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, Rowe SP, Ross AE, Gorin MA, Deville C, Greco SC, Wang H, Denmeade SR, Paller CJ, Dipasquale S, et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. Jama Oncology. PMID 32215577 DOI: 10.1001/Jamaoncol.2020.0147  0.582
2020 Markowski MC, Shenderov E, Eisenberger MA, Kachhap S, Pardoll DM, Denmeade SR, Antonarakis ES. Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer. The Prostate. PMID 31972048 DOI: 10.1002/Pros.23955  0.562
2020 Deek MP, Hasan H, Phillips R, Hobbs RF, Kiess AP, Wang H, Thompson ED, Powell J, Deville C, Greco SC, Song D, Rowe SP, Denmeade SR, Markowski MC, Antonarakis ES, et al. A phase II randomized trial of RAdium-223 dichloride and SABR versus SABR for oligomEtastatic prostate caNcerS (RAVENS). Journal of Clinical Oncology. 38: TPS5586-TPS5586. DOI: 10.1200/jco.2020.38.15_suppl.tps5586  0.388
2020 Markowski MC, Wang H, Schweizer MT, Carducci MA, Paller CJ, Teply BA, Eisenberger MA, Luo J, Antonarakis ES, Denmeade SR. RESTORE: A single-arm, open-label phase II trial of bipolar androgen therapy (BAT) in men with metastatic castration resistant prostate cancer (mCRPC)—A comparison of post-abiraterone (Abi) versus post-enzalutamide (Enza) patients (Pts). Journal of Clinical Oncology. 38: 5576-5576. DOI: 10.1200/Jco.2020.38.15_Suppl.5576  0.432
2020 Denmeade SR, Wang H, Cao H, Fu W, Wang T, Abdallah R, Bolejack V, Agarwal N, Smith DC, Schweizer MT, Stein MN, Assikis VJ, Flaig TW, Szmulewitz RZ, Holzbeierlein J, et al. TRANSFORMER: Bipolar androgen therapy (BAT) versus enzalutamide (E) for castration-resistant metastatic prostate cancer (mCRPC). Journal of Clinical Oncology. 38: 5517-5517. DOI: 10.1200/Jco.2020.38.15_Suppl.5517  0.403
2020 Marshall CH, Yegnasubramanian S, Wang H, Durham J, Wang T, Damico R, D'Alessio FR, Sidhaye VK, Pekosz A, Mankowski JL, Klein SL, Murli S, Jaffee EM, Denmeade SR. Abstract IA09: A phase II trial to promote recovery from COVID-19 with endocrine therapy Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Covid-19-Ia09  0.407
2020 Kumar R, Boyapati K, Thomas N, Topiwala D, Kanacharoen S, Owoyemi O, Coffey M, Carducci M, Markowski MC, Antonarakis ES, Pardoll D, Denmeade S, Kachhap SK. Abstract 2410: Supraphysiological androgens induce ferroptotic cell death in prostate cancer cells Cancer Research. 80: 2410-2410. DOI: 10.1158/1538-7445.Am2020-2410  0.619
2019 Isaacs JT, Brennen WN, Denmeade SR. Serial bipolar androgen therapy (sBAT) using cyclic supraphysiologic testosterone (STP) to treat metastatic castration-resistant prostate cancer (mCRPC). Annals of Translational Medicine. 7: S311. PMID 32016030 DOI: 10.21037/Atm.2019.10.32  0.8
2019 Velho PI, Lim D, Wang H, Park JC, Kaur HB, Almutairi F, Carducci MA, Denmeade SR, Markowski MC, Isaacs WB, Antonarakis ES, Pritchard CC, Eisenberger MA, Lotan TL. Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical Prostatectomy. Jco Precision Oncology. 3. PMID 31650100 DOI: 10.1200/PO.19.00081  0.411
2019 Deek MP, Yu C, Phillips R, Song DY, Deville C, Greco S, DeWeese TL, Antonarakis ES, Markowski M, Paller C, Denmeade S, Carducci M, Walsh PC, Pienta KJ, Eisenberger M, et al. Radiotherapy In The Definitive Management Of Oligometastatic Prostate Cancer: The Johns Hopkins Experience. International Journal of Radiation Oncology, Biology, Physics. PMID 31419509 DOI: 10.1016/J.Ijrobp.2019.08.008  0.561
2019 Paller CJ, Piana D, Eshleman JR, Riel S, Denmeade SR, Isaacsson Velho P, Rowe SP, Pomper MG, Antonarakis ES, Luo J, Eisenberger MA. A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer. The Prostate. PMID 31361358 DOI: 10.1002/Pros.23883  0.636
2019 Chatterjee P, Schweizer MT, Lucas JM, Coleman I, Nyquist MD, Frank SB, Tharakan R, Mostaghel E, Luo J, Pritchard CC, Lam HM, Corey E, Antonarakis ES, Denmeade SR, Nelson PS. Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage. The Journal of Clinical Investigation. 130. PMID 31310591 DOI: 10.1172/Jci127613  0.436
2019 Isaacsson Velho P, Fu W, Wang H, Mirkheshti N, Qazi F, Lima FAS, Shaukat F, Carducci MA, Denmeade SR, Paller CJ, Markowski MC, Marshall CH, Eisenberger MA, Antonarakis ES. Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer. European Urology. PMID 31176623 DOI: 10.1016/J.Eururo.2019.05.032  0.557
2019 Torquato S, Pallavajjala A, Goldstein A, Toro PV, Silberstein JL, Lee J, Nakazawa M, Waters I, Chu D, Shinn D, Groginski T, Hughes RM, Simons BW, Khan H, Feng Z, ... ... Denmeade SR, et al. Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer. Jco Precision Oncology. 3. PMID 31131348 DOI: 10.1200/PO.18.00227  0.383
2019 Rogers O, Yen H, Solomon A, Drake C, Denmeade S. An IL-2 proaerolysin fusion toxin that selectively eliminates regulatory t cells to enhance antitumor immune response. The Prostate. PMID 31059598 DOI: 10.1002/Pros.23819  0.509
2019 Teply BA, Qiu F, Antonarakis ES, Carducci MA, Denmeade SR. Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU-AA-302. The Prostate. 79: 929-933. PMID 31059588 DOI: 10.1002/Pros.23798  0.448
2019 Brennen WN, Schweizer MT, Wang H, Bivalacqua TJ, Partin AW, Lim SJ, Chapman C, Abdallah R, Levy O, Bhowmick NA, Karp JM, De Marzo A, Isaacs JT, Denmeade SR. In Reply to the Letter to the Editor from Raj et al.: Clinical Evidence Indicates Allogeneic Mesenchymal Stem Cells Do Not Pose a Significant Risk for Cancer Progression in the Context of Cell-Based Drug Delivery. Stem Cells Translational Medicine. PMID 30925030 DOI: 10.1002/Sctm.19-0068  0.661
2019 Akinboye ES, Brennen WN, Denmeade SR, Isaacs JT. Albumin-linked prostate-specific antigen-activated thapsigargin- and niclosamide-based molecular grenades targeting the microenvironment in metastatic castration-resistant prostate cancer. Asian Journal of Urology. 6: 99-108. PMID 30775253 DOI: 10.1016/J.Ajur.2018.11.004  0.819
2019 Schweizer MT, Wang H, Bivalacqua TJ, Partin AW, Lim SJ, Chapman C, Abdallah R, Levy O, Bhowmick NA, Karp JM, De Marzo A, Isaacs JT, Brennen WN, Denmeade SR. A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer. Stem Cells Translational Medicine. PMID 30735000 DOI: 10.1002/Sctm.18-0230  0.735
2019 Isaacsson Velho P, Lotan TL, Markowski MC, Antonarakis ES, Carducci MA, Denmeade SR, Wang H, Lim D, Pritchard C, Eisenberger MA. Genomic analysis and clinical outcomes of Primary Gleason Pattern 5 (PG5) prostate cancer (PCa) treated with radical prostatectomy (RP). Journal of Clinical Oncology. 37: 54-54. DOI: 10.1200/Jco.2019.37.7_Suppl.54  0.338
2019 Schweizer MT, Antonarakis ES, Eisenberger MA, Nelson P, Luo J, Pritchard C, Denmeade SR. Genomic determinants of sensitivity to bipolar androgen therapy (BAT) in castrate-resistant prostate cancer (CRPC). Journal of Clinical Oncology. 37: 200-200. DOI: 10.1200/Jco.2019.37.7_Suppl.200  0.364
2019 Chen J, Joshua AM, Denmeade SR, Antonarakis ES, Crumbaker M. High dose testosterone in men with metastatic castrate-resistant prostate cancer (mCRPC) and homologous recombination deficiency (HRD). Journal of Clinical Oncology. 37: TPS5095-TPS5095. DOI: 10.1200/Jco.2019.37.15_Suppl.Tps5095  0.442
2019 Isaacsson Velho P, Mirkheshti N, Qazi F, Shaukat F, Fu W, Wang H, Carducci MA, Markowski MC, Denmeade SR, Marshall CH, Lotan TL, Eisenberger MA, Antonarakis ES. WNT activating pathway mutations confer resistance to first-line antiandrogen therapy in castration-resistant prostate cancer (CRPC). Journal of Clinical Oncology. 37: 5068-5068. DOI: 10.1200/Jco.2019.37.15_Suppl.5068  0.351
2019 Mendonca J, Owoyemi O, Rosen M, Carducci M, Markowski M, Antonarakis E, Pardoll D, Denmeade S, Kachhap SK. Abstract 517: Supraphysiological androgens activate innate immune signaling in prostate cancer Immunology. DOI: 10.1158/1538-7445.Sabcs18-517  0.559
2019 Phillips R, Lim S, Shi W, Antonarakis E, Rowe S, Gorin M, Deville C, Greco S, Denmeade S, Paller C, DeWeese T, Song D, Wang H, Carducci M, Pienta K, et al. Primary Outcomes of a Phase II Randomized Trial of Observation Versus Stereotactic Ablative RadiatIon for OLigometastatic Prostate CancEr (ORIOLE) International Journal of Radiation Oncology*Biology*Physics. 105: 681. DOI: 10.1016/J.Ijrobp.2019.08.031  0.378
2019 Yu C, Deek M, Phillips R, Song D, Deville C, Greco S, DeWeese T, Antonarakis E, Markowski M, Paller C, Denmeade S, Carudcci M, Pienta K, Eisenberger M, Tran P. Clinical Outcomes in Oligometastatic Prostate Cancer Following Definitive Radiation Therapy International Journal of Radiation Oncology*Biology*Physics. 105: E573-E574. DOI: 10.1016/J.Ijrobp.2019.06.1243  0.421
2018 Isaacsson Velho P, Qazi F, Hassan S, Carducci MA, Denmeade SR, Markowski MC, Thorek DL, DeWeese TL, Song DY, Tran PT, Eisenberger MA, Antonarakis ES. Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects. European Urology. PMID 30293905 DOI: 10.1016/J.Eururo.2018.09.040  0.479
2018 Krueger TEG, Thorek DLJ, Denmeade SR, Isaacs JT, Brennen WN. Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise. Stem Cells Translational Medicine. PMID 30070053 DOI: 10.1002/Sctm.18-0024  0.69
2018 Denmeade SR. Bipolar androgen therapy in the treatment of prostate cancer. Clinical Advances in Hematology & Oncology : H&O. 16: 408-411. PMID 30067610  0.505
2018 Rogers OC, Anthony L, Rosen DM, Brennen WN, Denmeade SR. PSA-selective activation of cytotoxic human serine proteases within the tumor microenvironment as a therapeutic strategy to target prostate cancer. Oncotarget. 9: 22436-22450. PMID 29854290 DOI: 10.18632/Oncotarget.25091  0.83
2018 Kostova MB, Brennen WN, Lopez D, Anthony L, Wang H, Platz E, Denmeade SR. PSA-alpha-2-macroglobulin complex is enzymatically active in the serum of patients with advanced prostate cancer and can degrade circulating peptide hormones. The Prostate. PMID 29659051 DOI: 10.1002/Pros.23539  0.805
2018 Teply BA, Qiu F, Antonarakis ES, Carducci MA, Denmeade SR. Visceral metastases on abiraterone vs. placebo: A post-hoc analysis of mode of radiographic progression in COU-AA-302. Journal of Clinical Oncology. 36: 194-194. DOI: 10.1200/Jco.2018.36.6_Suppl.194  0.476
2018 Tran P, Radwan N, Phillips R, Ross A, Rowe S, Gorin M, Antonarakis E, DeVille C, Greco S, Denmeade S, Paller C, Song D, Diehn M, Wang H, Carducci M, et al. OC-0505: Interim results of a randomized trial of observation versus SABR for oligometastatic prostate cancer Radiotherapy and Oncology. 127: S261. DOI: 10.1016/S0167-8140(18)30815-6  0.473
2018 Phillips R, Radwan N, Ross A, Rowe S, Gorin M, Antonarakis E, Deville C, Greco S, Denmeade S, Paller C, Song D, Wang H, Carudcci M, Pienta K, Pomper M, et al. Interim Results of a Randomized Trial of Observation Versus SABR for Castration-Sensitive Oligometastatic Prostate Cancer International Journal of Radiation Oncology*Biology*Physics. 102: e134-e135. DOI: 10.1016/J.Ijrobp.2018.07.257  0.476
2017 Teply BA, Wang H, Luber B, Sullivan R, Rifkind I, Bruns A, Spitz A, DeCarli M, Sinibaldi V, Pratz CF, Lu C, Silberstein JL, Luo J, Schweizer MT, Drake CG, ... ... Denmeade SR, et al. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. The Lancet. Oncology. PMID 29248236 DOI: 10.1016/S1470-2045(17)30906-3  0.594
2017 Akinboye ES, Rosen MD, Bakare O, Denmeade SR. Anticancer activities of emetine prodrugs that are proteolytically activated by the prostate specific antigen (PSA) and evaluation of in vivo toxicity of emetine derivatives. Bioorganic & Medicinal Chemistry. PMID 29153549 DOI: 10.1016/J.Bmc.2017.11.015  0.576
2017 Paller CJ, Zhou XC, Heath EI, Taplin ME, Mayer T, Stein MN, Bubley GJ, Pili R, Hudson T, Kakarla R, Abbas MM, Anders NM, Dowling D, King S, Bruns AB, ... ... Denmeade SR, et al. Muscadine Grape Skin Extract in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29113986 DOI: 10.1158/1078-0432.Ccr-17-1100  0.565
2017 Isaacs JT, Brennen WN, Denmeade SR. Rationale for Bipolar Androgen Therapy (BAT) for Metastatic Prostate Cancer. Cell Cycle (Georgetown, Tex.). 0. PMID 28820291 DOI: 10.1080/15384101.2017.1360645  0.798
2017 Radwan N, Phillips R, Ross A, Rowe SP, Gorin MA, Antonarakis ES, Deville C, Greco S, Denmeade S, Paller C, Song DY, Diehn M, Wang H, Carducci M, Pienta KJ, et al. A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE). Bmc Cancer. 17: 453. PMID 28662647 DOI: 10.1186/s12885-017-3455-6  0.526
2017 Brennen WN, Zhang B, Kulac I, Kisteman LN, Antony L, Wang H, Meeker AK, De Marzo AM, Garraway IP, Denmeade SR, Isaacs JT. Mesenchymal stem cell infiltration during neoplastic transformation of the human prostate. Oncotarget. PMID 28493842 DOI: 10.18632/Oncotarget.17362  0.788
2017 Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Zhu Y, Silberstein JL, Taylor MN, Maughan BL, Denmeade SR, Pienta KJ, Paller CJ, Carducci MA, Eisenberger MA, Luo J. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016701961. PMID 28384066 DOI: 10.1200/Jco.2016.70.1961  0.453
2017 Schweizer MT, Antonarakis ES, Denmeade SR. Bipolar Androgen Therapy: A Paradoxical Approach for the Treatment of Castration-resistant Prostate Cancer. European Urology. PMID 28365160 DOI: 10.1016/J.Eururo.2017.03.022  0.567
2017 Gorin MA, Rowe SP, Denmeade SR. Clinical Applications of Molecular Imaging in the Management of Prostate Cancer. Pet Clinics. 12: 185-192. PMID 28267452 DOI: 10.1016/J.Cpet.2016.11.001  0.513
2017 Ajiboye AS, Esopi D, Yegnasubramanian S, Denmeade SR. Androgen Receptor Splice Variants Are Not Substrates of Nonsense-Mediated Decay. The Prostate. PMID 28224650 DOI: 10.1002/Pros.23323  0.391
2017 Goldstein A, Valda Toro P, Lee J, Silberstein JL, Nakazawa M, Waters I, Cravero K, Chu D, Cochran RL, Kim M, Shinn D, Torquato S, Hughes RM, Pallavajjala A, Carducci MA, ... ... Denmeade SR, et al. Detection fidelity of AR mutations in plasma derived cell-free DNA. Oncotarget. PMID 28152506 DOI: 10.18632/Oncotarget.14926  0.365
2017 Paller CJ, Heath EI, Taplin M, Stein MN, Bubley GJ, Pili R, Mayer TM, Zhou XC, Hudson T, Abbas M, Anders N, Dowling D, KIng S, Drake CG, Antonarakis ES, ... ... Denmeade SR, et al. A phase II study of muscadine grape skin extract in men with biochemically recurrent prostate cancer. Journal of Clinical Oncology. 35: 248-248. DOI: 10.1200/Jco.2017.35.6_Suppl.248  0.429
2017 Teply BA, Wang H, Sullivan R, Rifkind I, Bruns A, Decarli M, Sinibaldi VJ, Pratz CF, Luo J, Carducci MA, Paller CJ, Antonarakis ES, Eisenberger MA, Denmeade SR. Phase II study of bipolar androgen therapy (BAT) in men with metastatic castration-resistant prostate cancer (mCRPC) and progression on enzalutamide (enza). Journal of Clinical Oncology. 35: 5017-5017. DOI: 10.1200/Jco.2017.35.15_Suppl.5017  0.45
2017 Na R, Zheng S, Han M, Yu H, Jiang D, Shah S, Ewing C, Zhang L, Novakovic K, Petkewicz J, Gulukota K, Helseth D, Quinn M, Humphries E, Wiley K, ... ... Denmeade S, et al. Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death European Urology Supplements. 16: e832-e833. DOI: 10.1016/S1569-9056(17)30541-9  0.371
2016 Na R, Zheng SL, Han M, Yu H, Jiang D, Shah S, Ewing CM, Zhang L, Novakovic K, Petkewicz J, Gulukota K, Helseth DL, Quinn M, Humphries E, Wiley KE, ... ... Denmeade SR, et al. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. European Urology. PMID 27989354 DOI: 10.1016/S1569-9056(17)30541-9  0.505
2016 Teply BA, Kachhap S, Eisenberger MA, Denmeade SR. Extreme Response to High-dose Testosterone in BRCA2- and ATM-mutated Prostate Cancer. European Urology. PMID 27692705 DOI: 10.1016/J.Eururo.2016.09.020  0.51
2016 Schweizer MT, Wang H, Luber B, Nadal R, Spitz A, Rosen DM, Cao H, Antonarakis ES, Eisenberger MA, Carducci MA, Paller C, Denmeade SR. Bipolar androgen therapy for men with androgen ablation naïve prostate cancer: Results from the phase II BATMAN study. The Prostate. PMID 27338150 DOI: 10.1002/Pros.23209  0.606
2016 Sangster-Guity N, Tu-Sekine B, Raben DM, Denmeade SR, Williams SA. Mutational analysis of prostate-specific antigen defines the intrinsic proteolytic activity of the proPSA zymogen. The Prostate. PMID 27273171 DOI: 10.1002/Pros.23216  0.618
2016 Mahalingam D, Wilding G, Denmeade S, Sarantopoulas J, Cosgrove D, Cetnar J, Azad N, Bruce J, Kurman M, Allgood VE, Carducci M. Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours. British Journal of Cancer. 114: 986-94. PMID 27115568 DOI: 10.1038/Bjc.2016.72  0.333
2016 Levy O, Brennen WN, Han E, Rosen DM, Musabeyezu J, Safaee H, Ranganath S, Ngai J, Heinelt M, Milton Y, Wang H, Bhagchandani SH, Joshi N, Bhowmick N, Denmeade SR, et al. A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer. Biomaterials. 91: 140-150. PMID 27019026 DOI: 10.1016/J.Biomaterials.2016.03.023  0.776
2016 Akinboye ES, Brennen WN, Rosen DM, Bakare O, Denmeade SR. Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy. The Prostate. PMID 26835873 DOI: 10.1002/Pros.23162  0.772
2016 Schweizer MT, Wang H, Luber B, Nadal RM, Spitz AN, Rosen DM, Cao H, Antonarakis ES, Eisenberger MA, Carducci MA, Paller CJ, Denmeade SR. Bipolar androgen therapy (BAT) in men with hormone sensitive (HS) prostate cancer (PC). Journal of Clinical Oncology. 34: 236-236. DOI: 10.1200/Jco.2016.34.2_Suppl.236  0.47
2016 Park JC, Lotan TL, Blackford AL, Carducci MA, Denmeade SR, Eisenberger MA. The natural history and clinical/molecular characterization of primary Gleason pattern 5 (G5) prostate cancer (PCa) treated with radical prostatectomy (RP). Journal of Clinical Oncology. 34: e16576-e16576. DOI: 10.1200/Jco.2016.34.15_Suppl.E16576  0.487
2016 Lee EK, Teply BA, Maughan BL, Carducci MA, Antonarakis ES, Denmeade SR. Patterns of metastatic disease progression after treatment with first-line enzalutamide or abiraterone in castration-resistant prostate cancer (CRPC). Journal of Clinical Oncology. 34: e16539-e16539. DOI: 10.1200/Jco.2016.34.15_Suppl.E16539  0.532
2016 Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Zhu Y, Silberstein JL, Taylor MN, Maughan BL, Paller CJ, Denmeade SR, Pienta KJ, Carducci MA, Eisenberger MA, Luo J. AR-V7 and efficacy of abiraterone (Abi) and enzalutamide (Enza) in castration-resistant prostate cancer (CRPC): Expanded analysis of the Johns Hopkins cohort. Journal of Clinical Oncology. 34: 5012-5012. DOI: 10.1200/Jco.2016.34.15_Suppl.5012  0.472
2016 Pruitt FL, Brennen N, Antony L, Rosen DM, Denmeade S, Isaacs J. Abstract 2076: Albumin-linked proaerolysin based molecular grenades: A systemic therapeutic for disseminated castration resistant prostate cancer Cancer Research. 76: 2076-2076. DOI: 10.1158/1538-7445.Am2016-2076  0.562
2016 Brennen N, Levy O, Han E, Rosen DM, Musabeyezu J, Safaee H, Ranganath S, Ngai J, Heinelt M, Billett S, Bhowmick N, Denmeade S, Karp J, Isaacs J. Abstract 2067: Attacking prostate cancer with a prodrug-doped cellular Trojan horse Cancer Research. 76: 2067-2067. DOI: 10.1158/1538-7445.Am2016-2067  0.625
2016 Denmeade S, Antonarakis E, Paller C, Wang H, Benjamin T, Drake C, Carducci M, Eisenberger M. A phase II study of rapid cycling high dose testosterone (Bipolar Androgen Therapy) in men with metastatic castrate-resistant prostate cancer (mCRPC) resistant to abiraterone and/or enzalutamide European Journal of Cancer. 69: S15. DOI: 10.1016/S0959-8049(16)32631-4  0.427
2016 Akinboye ES, Brennen WN, Rosen DM, Bakare O, Denmeade SR. Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy Prostate. DOI: 10.1002/pros.23162  0.625
2016 Nadal R, Tsai HL, Sinibaldi VJ, Paller CJ, Antonarakis ES, Denmeade SR, Carducci MA, Eisenberger MA. Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies Prostate. 76: 512-520. DOI: 10.1002/pros.23141  0.444
2015 Akinboye ES, Bamji ZD, Kwabi-Addo B, Ejeh D, Copeland RL, Denmeade SR, Bakare O. Design, synthesis and cytotoxicity studies of dithiocarbamate ester derivatives of emetine in prostate cancer cell lines. Bioorganic & Medicinal Chemistry. 23: 5839-45. PMID 26187015 DOI: 10.1016/J.Bmc.2015.06.072  0.482
2015 Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. Jama Oncology. PMID 26181238 DOI: 10.1001/Jamaoncol.2015.1341  0.565
2015 Paller CJ, Rudek MA, Zhou XC, Wagner WD, Hudson TS, Anders N, Hammers HJ, Dowling D, King S, Antonarakis ES, Drake CG, Eisenberger MA, Denmeade SR, Rosner GL, Carducci MA. A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination. The Prostate. PMID 26012728 DOI: 10.1002/Pros.23024  0.607
2015 Barakat DJ, Zhang J, Barberi T, Denmeade SR, Friedman AD, Paz-Priel I. CCAAT/Enhancer binding protein β controls androgen-deprivation-induced senescence in prostate cancer cells. Oncogene. PMID 25772238 DOI: 10.1038/Onc.2015.41  0.478
2015 Schweizer MT, Antonarakis ES, Wang H, Ajiboye AS, Spitz A, Cao H, Luo J, Haffner MC, Yegnasubramanian S, Carducci MA, Eisenberger MA, Isaacs JT, Denmeade SR. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Science Translational Medicine. 7: 269ra2. PMID 25568070 DOI: 10.1126/Scitranslmed.3010563  0.571
2015 LeBeau AM, Denmeade SR. Protease-activated pore-forming peptides for the treatment and imaging of prostate cancer. Molecular Cancer Therapeutics. 14: 659-68. PMID 25537662 DOI: 10.1158/1535-7163.Mct-14-0744  0.832
2015 Doan NT, Paulsen ES, Sehgal P, Møller JV, Nissen P, Denmeade SR, Isaacs JT, Dionne CA, Christensen SB. Targeting thapsigargin towards tumors. Steroids. 97: 2-7. PMID 25065587 DOI: 10.1016/J.Steroids.2014.07.009  0.605
2015 Antonarakis ES, Lu C, Chen Y, Luber B, Wang H, Nakazawa M, De Marzo AM, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. AR splice variant 7 (AR-V7) and response to taxanes in men with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 33: 138-138. DOI: 10.1200/Jco.2015.33.7_Suppl.138  0.397
2015 Teply BA, Antonarakis ES, Carducci MA, Paller CJ, Wang H, Cao H, Spitz AN, Luo J, Eisenberger MA, Denmeade SR. A randomized phase II study comparing bipolar androgen therapy vs. enzalutamide in asymptomatic men with castration resistant metastatic prostate cancer: The TRANSFORMER trial. Journal of Clinical Oncology. 33: TPS5079-TPS5079. DOI: 10.1200/Jco.2015.33.15_Suppl.Tps5079  0.582
2015 Barakat DJ, Zhang J, Friedman AD, Denmeade SR, Paz-Priel I. Abstract 85: CCAAT/enhancer binding protein beta facilitates castrate-resistant prostate cancer cell growth and sensitivity to mTOR inhibitors Cancer Research. 75: 85-85. DOI: 10.1158/1538-7445.Am2015-85  0.488
2015 Teply BA, Luber B, Denmeade SR, Antonarakis ES. The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer Prostate Cancer and Prostatic Diseases. DOI: 10.1038/Pcan.2015.53  0.586
2014 Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, ... ... Denmeade SR, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. The New England Journal of Medicine. 371: 1028-38. PMID 25184630 DOI: 10.1056/Nejmoa1315815  0.523
2014 Nadal R, Zhang Z, Rahman H, Schweizer MT, Denmeade SR, Paller CJ, Carducci MA, Eisenberger MA, Antonarakis ES. Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. The Prostate. 74: 1560-8. PMID 25176007 DOI: 10.1002/Pros.22874  0.522
2014 Brennen WN, Rosen DM, Chaux A, Netto GJ, Isaacs JT, Denmeade SR. Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human cancer. The Prostate. 74: 1308-19. PMID 25053236 DOI: 10.1002/Pros.22847  0.697
2014 Paller CJ, Olatoye D, Xie S, Zhou X, Denmeade SR, Eisenberger MA, Antonarakis ES, Carducci MA, Rosner GL. The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer Prostate Cancer and Prostatic Diseases. 17: 28-33. PMID 24100642 DOI: 10.1038/pcan.2013.40  0.357
2014 Schweizer MT, Antonarakis ES, Wang H, Spitz AN, Cao H, Pacheco A, Eisenberger MA, Carducci MA, Denmeade SR. A pilot study of supraphysiologic testosterone (T) and oral etoposide (E) in men with castrate-resistant prostate cancer (CRPC). Journal of Clinical Oncology. 32: 45-45. DOI: 10.1200/Jco.2014.32.4_Suppl.45  0.421
2014 Paller CJ, Rudek MA, Antonarakis ES, Eisenberger MA, Hammers HJ, Zhou XC, Dowling D, King S, Hudock S, Denmeade SR, Wagner WD, Rosner GL, Hudson T, Carducci MA. A phase I trial of muscadine grape skin in men with biochemically recurrent prostate cancer. Journal of Clinical Oncology. 32: 263-263. DOI: 10.1200/Jco.2014.32.4_Suppl.263  0.461
2014 Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Chen Y, Roeser JC, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, ... Denmeade SR, et al. Androgen receptor splice variant, AR-V7, and resistance to enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 32: 5001-5001. DOI: 10.1200/Jco.2014.32.15_Suppl.5001  0.476
2014 Brennen WN, Levy O, Ranganath S, Schweizer M, Rosen M, Billet S, Bhowmick N, Denmeade S, Karp J, Isaacs J. Abstract 699: Mesenchymal stem cells (MSC) as cell-based vectors for PSA-activated proaerolysin to sites of prostate cancer Cancer Research. 74: 699-699. DOI: 10.1158/1538-7445.Am2014-699  0.594
2014 Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Fedor HL, Lotan TL, Marzo AMD, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, et al. Abstract 2910: Androgen receptor splice variant-7 predicts resistance to enzalutamide in patients with castration-resistant prostate cancer Cancer Research. 74: 2910-2910. DOI: 10.1158/1538-7445.Am2014-2910  0.523
2014 Antonarakis E, Lu C, Wang H, Luber B, Nakazawa M, Roeser J, Chen Y, Fedor H, Lotan T, Zheng Q, De Marzo A, Isaacs J, Isaacs W, Nadal R, Paller C, ... Denmeade S, et al. Ar-V7 Splice Variant and Resistance to Enzalutamide and Abiraterone in Men with Metastatic Castration-Resistant Prostate Cancer (Mcrpc): Overall Survival Results Annals of Oncology. 25: v1. DOI: 10.1093/Annonc/Mdu438.23  0.429
2014 Denmeade S, Antonarakis E, Eisenberger M, Carducci M, Wang H, Paller C, Isaacs J, Schweizer M. 434 Bipolar androgen therapy for men with castration sensitive and castration resistant prostate cancer: Reversing resistance and maintaining sensitivity to androgen ablative therapies European Journal of Cancer. 50: 143. DOI: 10.1016/S0959-8049(14)70560-X  0.426
2013 Brennen WN, Denmeade SR, Isaacs JT. Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment. Endocrine-Related Cancer. 20: R269-90. PMID 23975882 DOI: 10.1530/Erc-13-0151  0.748
2013 Kostova MB, Rosen DM, Chen Y, Mease RC, Denmeade SR. Structural optimization, biological evaluation, and application of peptidomimetic prostate specific antigen inhibitors. Journal of Medicinal Chemistry. 56: 4224-35. PMID 23692593 DOI: 10.1021/Jm301718C  0.625
2013 Wang GM, Wong HY, Konishi H, Blair BG, Abukhdeir AM, Gustin JP, Rosen DM, Denmeade SR, Rasheed Z, Matsui W, Garay JP, Mohseni M, Higgins MJ, Cidado J, Jelovac D, et al. Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation. Cancer Research. 73: 3248-61. PMID 23580570 DOI: 10.1158/0008-5472.Can-12-1578  0.322
2013 Manning ML, Williams SA, Jelinek CA, Kostova MB, Denmeade SR. Proteolysis of complement factors iC3b and C5 by the serine protease prostate-specific antigen in prostatic fluid and seminal plasma. Journal of Immunology (Baltimore, Md. : 1950). 190: 2567-74. PMID 23401592 DOI: 10.4049/Jimmunol.1200856  0.757
2013 Brennen WN, Chen S, Denmeade SR, Isaacs JT. Quantification of Mesenchymal Stem Cells (MSCs) at sites of human prostate cancer. Oncotarget. 4: 106-17. PMID 23362217 DOI: 10.18632/Oncotarget.805  0.752
2013 Elhilali MM, Pommerville P, Yocum RC, Merchant R, Roehrborn CG, Denmeade SR. Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia. The Journal of Urology. 189: 1421-6. PMID 23142202 DOI: 10.1016/J.Juro.2012.11.003  0.543
2013 Nam S, Sangster-Guity N, Ewachiw TE, Denmeade SR, Williams SA. Abstract 5058: Expansion and validation of the prostate-specific antigen substrate degradome. Cancer Research. 73: 5058-5058. DOI: 10.1158/1538-7445.Am2013-5058  0.586
2013 Mahalingam D, Cetnar J, Wilding G, Denmeade S, Sarantopoulos J, Kurman M, Carducci M. Abstract B244: A first-in-human phase 1 clinical study of G-202, a thapsigargin-based Prostate-Specific Membrane Antigen (PSMA) activated prodrug, in patients with advanced solid tumors. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B244  0.341
2012 Brennen WN, Rosen DM, Wang H, Isaacs JT, Denmeade SR. Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug. Journal of the National Cancer Institute. 104: 1320-34. PMID 22911669 DOI: 10.1093/Jnci/Djs336  0.68
2012 Akinboye ES, Rosen MD, Denmeade SR, Kwabi-Addo B, Bakare O. Design, synthesis, and evaluation of pH-dependent hydrolyzable emetine analogues as treatment for prostate cancer. Journal of Medicinal Chemistry. 55: 7450-9. PMID 22867001 DOI: 10.1021/Jm300426Q  0.43
2012 Denmeade SR, Isaacs JT. Engineering enzymatically activated "molecular grenades" for cancer. Oncotarget. 3: 666-7. PMID 22837432 DOI: 10.18632/Oncotarget.562  0.51
2012 Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, Olesen C, Gurel B, Demarzo AM, Wilding G, Carducci MA, Dionne CA, Møller JV, Nissen P, Christensen SB, et al. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Science Translational Medicine. 4: 140ra86. PMID 22745436 DOI: 10.1126/Scitranslmed.3003886  0.822
2012 Morris MJ, Eisenberger MA, Pili R, Denmeade SR, Rathkopf D, Slovin SF, Farrelly J, Chudow JJ, Vincent M, Scher HI, Carducci MA. A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 23: 2714-9. PMID 22553195 DOI: 10.1093/Annonc/Mds078  0.486
2012 Isaacs JT, D'Antonio JM, Chen S, Antony L, Dalrymple SP, Ndikuyeze GH, Luo J, Denmeade SR. Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer. The Prostate. 72: 1491-505. PMID 22396319 DOI: 10.1002/Pros.22504  0.524
2012 Brennen WN, Isaacs JT, Denmeade SR. Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Molecular Cancer Therapeutics. 11: 257-66. PMID 22323494 DOI: 10.1158/1535-7163.Mct-11-0340  0.699
2012 Manning ML, Kostova M, Williams SA, Denmeade SR. Trypsin-like proteolytic contamination of commercially available psa purified from human seminal fluid. The Prostate. 72: 1233-8. PMID 22213008 DOI: 10.1002/Pros.22474  0.771
2012 Antonarakis ES, Carducci MA, Eisenberger MA, Denmeade SR, Slovin SF, Jelaca-Maxwell K, Vincent ME, Scher HI, Morris MJ. Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial. Cancer Chemotherapy and Pharmacology. 69: 763-71. PMID 22020316 DOI: 10.1007/S00280-011-1759-9  0.433
2012 Brandy Y, Ononiwu I, Adedeji D, Williams V, Mouamba C, Kanaan Y, Copeland RL, Wright DA, Butcher RJ, Denmeade SR, Bakare O. Synthesis and cytotoxic activities of some 2-arylnaphtho[2,3-d]oxazole-4,9-dione derivatives on androgen-dependent (LNCaP) and androgen-independent (PC3) human prostate cancer cell lines. Investigational New Drugs. 30: 1709-14. PMID 21243402 DOI: 10.1007/S10637-011-9635-3  0.554
2012 Paller CJ, Xie S, Olatoye D, Denmeade SR, Eisenberger MA, Antonarakis ES, Carducci MA, Rosner GL. The effect of PSA frequency and duration on PSA doubling time (PSADT) calculations in men with biochemically recurrent prostate cancer (BRPC) after definitive local therapy. Journal of Clinical Oncology. 30: 4559-4559. DOI: 10.1200/Jco.2012.30.15_Suppl.4559  0.454
2012 Armstrong AJ, Haggman M, Stadler WM, Gingrich JR, Assikis VJ, Polikoff J, Denmeade SR, George DJ, Andreou C, Clark WR, Sieber P, Agajanian R, Belkoff L, Damber J, Nordle O, et al. Tasquinimod and survival in men with metastatic castration-resistant prostate cancer: Results of long-term follow-up of a randomized phase II placebo-controlled trial. Journal of Clinical Oncology. 30: 4550-4550. DOI: 10.1200/Jco.2012.30.15_Suppl.4550  0.336
2012 Brennen WN, Denmeade SR, Isaacs JT. Abstract B21: Mesenchymal stem cells (MSCs) as a selective delivery vehicle for a PSA-activated protoxin for advanced prostate cancer Cancer Research. 72: B21-B21. DOI: 10.1158/1538-7445.PRCA2012-B21  0.471
2012 Chen S, Brennen N, Brodsky RA, Cheng L, Denmeade SR, Isaacs JT. Abstract 5699: Mesenchymal stem cells (MSCs) as a selective delivery vehicle for a PSA-activated protoxin for advanced prostate cancer Cancer Research. 72: 5699-5699. DOI: 10.1158/1538-7445.Am2012-5699  0.612
2012 Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, Olesen C, Gurel B, DeMarzo AM, Wilding G, Carducci MA, Dionne CA, Møller JV, Nissen P, Christensen SB, et al. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy (Science Translational Medicine) Science Translational Medicine. 4. DOI: 10.1126/Scitranslmed.3004546  0.829
2012 Denmeade S, Wang H, Spitz A, Pacheco A, Isaacs J, Carducci M, Antonarakis E. 297 Effectiveness of Acute Cycling of Supraphysiologic Testosterone Given Together with Etoposide in Men with Castration Resistant Prostate Cancer European Journal of Cancer. 48: 91. DOI: 10.1016/S0959-8049(12)72095-6  0.473
2011 Sinibaldi VJ, Huang P, Antonarakis ES, Carducci MA, Denmeade SR, Kim JJ, Eisenberger MA, Keizman D. PSA doubling time (PSADT) and serum testosterone (T) during intermittent androgen deprivation (IAD) in patients with biochemically relapsed prostate cancer (BRCP; M0): Potential predictive implications. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e15006. PMID 28020552 DOI: 10.1200/jco.2011.29.15_suppl.e15006  0.4
2011 Eisenberger MA, Huang P, Sinibaldi VJ, Carducci MA, Denmeade SR, Antonarakis ES, Kim JJ, Keizman D. Safety and efficacy of ketoconazole (K) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Contemporary experience and prognostic indicators. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e15007. PMID 28020551 DOI: 10.1200/jco.2011.29.15_suppl.e15007  0.402
2011 Keizman D, Huang P, Carducci MA, Denmeade SR, Eisenberger MA. Safety and efficacy of ketoconazole (K) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Contemporary experience and prognostic indicators. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 145. PMID 27968599 DOI: 10.1200/jco.2011.29.7_suppl.145  0.408
2011 Keizman D, Huang P, Antonarakis ES, Sinibaldi VJ, Carducci MA, Denmeade SR, Eisenberger MA. PSA doubling time (PSADT) and serum testosterone (T) during intermittent androgen deprivation (IAD) in patients with biochemically relapsed prostate cancer (BRCP; M0): Potential predictive implications. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 150. PMID 27968545 DOI: 10.1200/jco.2011.29.7_suppl.150  0.407
2011 Kim JJ, Keizman D, Denmeade SR, Antonarakis ES. The unfolding treatment landscape for men with castration-resistant prostate cancer. Clinical Investigation. 1: 1533-1544. PMID 23115711 DOI: 10.4155/Cli.11.138  0.571
2011 Keizman D, Huang P, Antonarakis ES, Sinibaldi V, Carducci MA, Denmeade S, Kim JJ, Walczak J, Eisenberger MA. The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen Deprivation Prostate. 71: 1608-1615. PMID 21432863 DOI: 10.1002/Pros.21377  0.581
2011 Williams SA, Jelinek CA, Litvinov I, Cotter RJ, Isaacs JT, Denmeade SR. Enzymatically active prostate-specific antigen promotes growth of human prostate cancers. The Prostate. 71: 1595-607. PMID 21394741 DOI: 10.1002/Pros.21375  0.632
2011 Denmeade SR, Egerdie B, Steinhoff G, Merchant R, Abi-Habib R, Pommerville P. Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. European Urology. 59: 747-54. PMID 21129846 DOI: 10.1016/J.Eururo.2010.11.024  0.543
2010 Hu R, Denmeade SR, Luo J. Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer. Expert Review of Endocrinology & Metabolism. 5: 753-764. PMID 21318111 DOI: 10.1586/Eem.10.49  0.59
2010 Keizman D, Zahurak M, Sinibaldi V, Carducci M, Denmeade S, Drake C, Pili R, Antonarakis ES, Hudock S, Eisenberger M. Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5269-76. PMID 20978144 DOI: 10.1158/1078-0432.Ccr-10-1928  0.573
2010 Denmeade SR, Isaacs JT. Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer. The Prostate. 70: 1600-7. PMID 20607766 DOI: 10.1002/Pros.21196  0.597
2010 Weiss MB, Vitolo MI, Mohseni M, Rosen DM, Denmeade SR, Park BH, Weber DJ, Bachman KE. Deletion of p53 in human mammary epithelial cells causes chromosomal instability and altered therapeutic response. Oncogene. 29: 4715-24. PMID 20562907 DOI: 10.1038/Onc.2010.220  0.3
2010 LeBeau AM, Kostova M, Craik CS, Denmeade SR. Prostate-specific antigen: an overlooked candidate for the targeted treatment and selective imaging of prostate cancer. Biological Chemistry. 391: 333-43. PMID 20180648 DOI: 10.1515/Bc.2010.044  0.84
2010 Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, Taplin ME, Bubley GJ, Kheoh T, Haqq C, Molina A, Anand A, Koscuiszka M, Larson SM, Schwartz LH, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 1496-501. PMID 20159814 DOI: 10.1200/Jco.2009.25.9259  0.587
2010 Williams SA, Xu Y, De Marzo AM, Isaacs JT, Denmeade SR. Prostate-specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate-targeted PSA/KLK2 double transgenic mice. The Prostate. 70: 788-96. PMID 20058238 DOI: 10.1002/Pros.21111  0.602
2010 Carducci MA, Eisenberger MA, Denmeade SR, Slovin SF, Jakobovits A, Vincent M, Scher HI, Morris MJ. Phase I dose-escalation study of AGS-1C4D4, an anti-PSCA human antibody in castration-resistant prostate cancer (CRPC). Journal of Clinical Oncology. 28: 4669-4669. DOI: 10.1200/jco.2010.28.15_suppl.4669  0.359
2010 Sinibaldi VJ, Keizman D, Carducci MA, Denmeade SR, Huang P, Eisenberger MA. Correlation between serum PSA and testosterone (T) kinetics in patients (pts) with biochemically relapsed prostate cancer (BRPC) (M0), after local treatment (tx), treated with intermittent androgen deprivation (IAD). Journal of Clinical Oncology. 28: 4641-4641. DOI: 10.1200/jco.2010.28.15_suppl.4641  0.429
2010 Keizman D, Sinibaldi VJ, Carducci MA, Denmeade SR, Drake CG, Pili R, Antonarakis ES, Hudock S, Zahurak M, Eisenberger MA. Phase I/II double-blinded randomized study to determine the tolerability and efficacy of two different doses of lenalidomide (Len) in biochemically relapsed prostate cancer (BRPC) (M0) patients (pts). Journal of Clinical Oncology. 28: 4554-4554. DOI: 10.1200/Jco.2010.28.15_Suppl.4554  0.339
2010 Williams SA, Jelinek CA, Cotter RJ, Isaacs JT, Denmeade SR. Abstract 2326: Loss of prostate-specific antigen slows growth and alters the extracellular proteome of LNCaP human prostate cancer cells Cancer Research. 70: 2326-2326. DOI: 10.1158/1538-7445.Am10-2326  0.608
2010 Brennen WN, Rosen M, Denmeade SR. Abstract 1424: Fibroblast activation protein alpha (FAP): Targeting the reactive stroma as a novel prodrug therapy Cancer Research. 70: 1424-1424. DOI: 10.1158/1538-7445.Am10-1424  0.45
2010 Elhilali M, Pommerville P, Steinhoff G, Egerdie B, Denmeade S, Merchant R, Buckley T, Abi-Habib RJ. 1787 EVALUATION OF TRANSPERINEAL PROSTATIC ADMINISTRATION OF A PSA-ACTIVATED PROTOXIN (PRX302) IN MEN WITH LUTS SECONDARY TO BPH Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.1698  0.551
2009 Danila DC, de Bono J, Ryan CJ, Denmeade S, Smith M, Taplin M, Bubley G, Molina A, Haqq C, Scher HI. Phase II multicenter study of abiraterone acetate (AA) plus prednisone therapy in docetaxel-treated castration-resistant prostate cancer (CRPC) patients (pts): Impact of prior ketoconazole (keto). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5048. PMID 27962949 DOI: 10.1200/Jco.2009.27.15_Suppl.5048  0.513
2009 Lin J, Sinibaldi VJ, Carducci MA, Denmeade S, Song D, Deweese T, Eisenberger MA. Phase I trial with a combination of docetaxel and ¹⁵³Sm-lexidronam in patients with castration-resistant metastatic prostate cancer. Urologic Oncology. 29: 670-5. PMID 19962920 DOI: 10.1016/J.Urolonc.2009.10.003  0.538
2009 Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, et al. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 7099-105. PMID 19887483 DOI: 10.1158/1078-0432.Ccr-09-1722  0.579
2009 Sharma P, Wisniewski A, Braga-Basaria M, Xu X, Yep M, Denmeade S, Dobs AS, DeWeese T, Carducci M, Basaria S. Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy. The Journal of Urology. 182: 2265-72. PMID 19758646 DOI: 10.1016/J.Juro.2009.07.030  0.518
2009 Singh P, LeBeau AM, Lilja H, Denmeade SR, Isaacs JT. Molecular insights into substrate specificity of prostate specific antigen through structural modeling. Proteins. 77: 984-93. PMID 19705489 DOI: 10.1002/Prot.22524  0.827
2009 LeBeau AM, Banerjee SR, Pomper MG, Mease RC, Denmeade SR. Optimization of peptide-based inhibitors of prostate-specific antigen (PSA) as targeted imaging agents for prostate cancer. Bioorganic & Medicinal Chemistry. 17: 4888-93. PMID 19541487 DOI: 10.1016/J.Bmc.2009.06.012  0.815
2009 LeBeau AM, Brennen WN, Aggarwal S, Denmeade SR. Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin. Molecular Cancer Therapeutics. 8: 1378-86. PMID 19417147 DOI: 10.1158/1535-7163.Mct-08-1170  0.809
2009 Vander Griend DJ, Antony L, Dalrymple SL, Xu Y, Christensen SB, Denmeade SR, Isaacs JT. Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells. Molecular Cancer Therapeutics. 8: 1340-9. PMID 19417145 DOI: 10.1158/1535-7163.Mct-08-1136  0.621
2009 LeBeau AM, Singh P, Isaacs JT, Denmeade SR. Prostate-specific antigen is a "chymotrypsin-like" serine protease with unique P1 substrate specificity. Biochemistry. 48: 3490-6. PMID 19281249 DOI: 10.1021/Bi9001858  0.824
2009 Christensen SB, Skytte DM, Denmeade SR, Dionne C, Møller JV, Nissen P, Isaacs JT. A Trojan horse in drug development: targeting of thapsigargins towards prostate cancer cells. Anti-Cancer Agents in Medicinal Chemistry. 9: 276-94. PMID 19275521 DOI: 10.2174/1871520610909030276  0.638
2009 Gustin JP, Karakas B, Weiss MB, Abukhdeir AM, Lauring J, Garay JP, Cosgrove D, Tamaki A, Konishi H, Konishi Y, Mohseni M, Wang G, Rosen DM, Denmeade SR, Higgins MJ, et al. Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proceedings of the National Academy of Sciences of the United States of America. 106: 2835-40. PMID 19196980 DOI: 10.1073/Pnas.0813351106  0.355
2009 Chandran SS, Williams SA, Denmeade SR. Extended-release PEG-luciferin allows for long-term imaging of firefly luciferase activity in vivo. Luminescence : the Journal of Biological and Chemical Luminescence. 24: 35-8. PMID 18780328 DOI: 10.1002/Bio.1060  0.354
2009 Denmeade S, Rosen D, Christensen S, Dionne C, Isaacs J. A Thapsigargin Prodrug Produces Sustained Growth Inhibition and Substantial Regression of Human Breast Cancers In Vivo with Minimal Host Toxicity. Cancer Research. 69: 5074-5074. DOI: 10.1158/0008-5472.Sabcs-09-5074  0.515
2009 Sedelaar J, Isaacs J, Denmeade S. 894 TARGETED IMAGING OF PROSTATE CANCER: SMART-BOMB PRO-DRUG MECHANISM European Urology Supplements. 8: 344. DOI: 10.1016/S1569-9056(09)60879-4  0.541
2009 Sedelaar J, Denmeade S, Isaacs J. 508 STEROIDOGENIC PROPERTIES OF PROSTATE CANCER CELL-LINES: PROOF FOR INTRACRINE ANDROGEN METABOLISM? European Urology Supplements. 8: 247. DOI: 10.1016/S1569-9056(09)60504-2  0.56
2009 Pommerville P, Egerdie B, Denmeade S, Merchant R, Buckley T, Abi-Habib R. 359 A PSA-ACTIVATED PROTO XIN (PRX302) ADMINISTERED TRANSPERINEALLY TO MEN WITH SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA IS WELL TOLERATED AND EXHIBITS SUSTAINED SIGNS OF ACTIVITY European Urology Supplements. 8: 210. DOI: 10.1016/S1569-9056(09)60362-6  0.551
2009 Pommerville PJ, Steinhoff G, Denmeade S, Merchant R, Buckley T, Abi-Habib RJ. A PSA-ACTIVATED PROTOXIN (PRX302) ADMINISTERED TRANSPERINEALLY TO MEN WITH BPH IS WELL TOLERATED AND INDUCES REDUCTION IN PROSTATE VOLUME AND SYMPTOMATIC RELIEF The Journal of Urology. 181: 704. DOI: 10.1016/S0022-5347(09)61968-6  0.547
2009 Denmeade S, Pommerville P, Steinhoff G, Egerdie B, Merchant R. MP-06.13: PRX302 is a Transperineally Administered, PSA-Activated Protoxin that Produces Symptomatic Relief in Men with Moderate to Severe BPH Urology. 74: S72-S73. DOI: 10.1016/J.Urology.2009.07.999  0.511
2008 Chandran SS, Banerjee SR, Mease RC, Pomper MG, Denmeade SR. Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA). Cancer Biology & Therapy. 7: 974-82. PMID 18698158 DOI: 10.4161/Cbt.7.6.5968  0.472
2008 LeBeau AM, Singh P, Isaacs JT, Denmeade SR. Potent and selective peptidyl boronic acid inhibitors of the serine protease prostate-specific antigen. Chemistry & Biology. 15: 665-74. PMID 18635003 DOI: 10.1016/J.Chembiol.2008.05.020  0.833
2008 Rathkopf D, Carducci MA, Morris MJ, Slovin SF, Eisenberger MA, Pili R, Denmeade SR, Kelsen M, Curley T, Halter M, Collins C, Fleisher M, Heller G, Baker SD, Scher HI. Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2959-65. PMID 18565882 DOI: 10.1200/Jco.2007.15.1928  0.595
2008 Aggarwal S, Brennen WN, Kole TP, Schneider E, Topaloglu O, Yates M, Cotter RJ, Denmeade SR. Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites. Biochemistry. 47: 1076-86. PMID 18095711 DOI: 10.1021/Bi701921B  0.731
2008 Singh P, Williams SA, Shah MH, Lectka T, Pritchard GJ, Isaacs JT, Denmeade SR. Mechanistic insights into the inhibition of prostate specific antigen by beta-lactam class compounds. Proteins. 70: 1416-28. PMID 17894328 DOI: 10.1002/Prot.21676  0.476
2007 Chandran SS, Nan A, Rosen DM, Ghandehari H, Denmeade SR. A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer. Molecular Cancer Therapeutics. 6: 2928-37. PMID 18025277 DOI: 10.1158/1535-7163.Mct-07-0392  0.629
2007 Kachhap SK, Faith D, Qian DZ, Shabbeer S, Galloway NL, Pili R, Denmeade SR, DeMarzo AM, Carducci MA. The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin. Plos One. 2: e844. PMID 17786215 DOI: 10.1371/Journal.Pone.0000844  0.375
2007 Collins C, Carducci MA, Eisenberger MA, Isaacs JT, Partin AW, Pili R, Sinibaldi VJ, Walczak JS, Denmeade SR. Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint. Cancer Biology & Therapy. 6: 1360-7. PMID 17786033 DOI: 10.4161/Cbt.6.9.4541  0.602
2007 Singh R, Browning JL, Abi-Habib R, Wong K, Williams SA, Merchant R, Denmeade SR, Buckley TJ, Frankel AE. Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity. Anti-Cancer Drugs. 18: 809-16. PMID 17581303 DOI: 10.1097/Cad.0B013E3280Bad82D  0.608
2007 Kumar SK, Williams SA, Isaacs JT, Denmeade SR, Khan SR. Modulating paclitaxel bioavailability for targeting prostate cancer. Bioorganic & Medicinal Chemistry. 15: 4973-84. PMID 17502149 DOI: 10.1016/J.Bmc.2007.04.029  0.633
2007 Bajaj GK, Zhang Z, Garrett-Mayer E, Drew R, Sinibaldi V, Pili R, Denmeade SR, Carducci MA, Eisenberger MA, DeWeese TL. Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy. Urology. 69: 526-31. PMID 17382158 DOI: 10.1016/J.Urology.2006.12.006  0.608
2007 Williams SA, Merchant RF, Garrett-Mayer E, Isaacs JT, Buckley JT, Denmeade SR. A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. Journal of the National Cancer Institute. 99: 376-85. PMID 17341729 DOI: 10.1093/Jnci/Djk065  0.604
2007 Williams SA, Singh P, Isaacs JT, Denmeade SR. Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? The Prostate. 67: 312-29. PMID 17143882 DOI: 10.1002/Pros.20531  0.635
2006 Aggarwal S, Singh P, Topaloglu O, Isaacs JT, Denmeade SR. A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity. Cancer Research. 66: 9171-7. PMID 16982760 DOI: 10.1158/0008-5472.Can-06-1520  0.653
2006 Singh P, Uzgare A, Litvinov I, Denmeade SR, Isaacs JT. Combinatorial androgen receptor targeted therapy for prostate cancer. Endocrine-Related Cancer. 13: 653-66. PMID 16954423 DOI: 10.1677/Erc.1.00797  0.545
2006 Sinibaldi VJ, Elza-Brown K, Schmidt J, Eisenberger MA, Rosenbaum E, Denmeade SR, Pili R, Walczak J, Baker SD, Zahurak M, Carducci MA. Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma American Journal of Clinical Oncology: Cancer Clinical Trials. 29: 395-398. PMID 16891869 DOI: 10.1097/01.Coc.0000225411.95479.B4  0.542
2006 Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4072-9. PMID 16818707 DOI: 10.1158/1078-0432.Ccr-06-0184  0.617
2006 Aggarwal S, Harden JL, Denmeade SR. Synthesis and screening of a random dimeric peptide library using the one-bead-one-dimer combinatorial approach. Bioconjugate Chemistry. 17: 335-40. PMID 16536463 DOI: 10.1021/Bc0502659  0.55
2006 Aggarwal S, Ricklis RM, Williams SA, Denmeade SR. Comparative study of PSMA expression in the prostate of mouse, dog, monkey, and human. The Prostate. 66: 903-10. PMID 16496413 DOI: 10.1002/Pros.20413  0.686
2006 Søhoel H, Jensen AM, Møller JV, Nissen P, Denmeade SR, Isaacs JT, Olsen CE, Christensen SB. Natural products as starting materials for development of second-generation SERCA inhibitors targeted towards prostate cancer cells. Bioorganic & Medicinal Chemistry. 14: 2810-5. PMID 16412648 DOI: 10.1016/J.Bmc.2005.12.001  0.419
2006 Janssen S, Rosen DM, Ricklis RM, Dionne CA, Lilja H, Christensen SB, Isaacs JT, Denmeade SR. Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug. The Prostate. 66: 358-68. PMID 16302271 DOI: 10.1002/Pros.20348  0.632
2006 Strock CJ, Park JI, Rosen DM, Ruggeri B, Denmeade SR, Ball DW, Nelkin BD. Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. The Journal of Clinical Endocrinology and Metabolism. 91: 79-84. PMID 16263812 DOI: 10.1210/Jc.2005-1882  0.37
2006 Aggarwal S, Cole T, Brennen W, Topaloglu O, Schneider E, Cotter R, Denmeade S. 527 POSTER Fibroblast Activation Protein (FAP) activated anti-stromal prodrug therapy for cancer European Journal of Cancer Supplements. 4: 160. DOI: 10.1016/S1359-6349(06)70532-8  0.676
2006 Williams S, Merchant N, Buckley J, Denmeade S. 526 POSTER A prostate-Specific Antigen (PSA) activated channel-forming toxin as therapy for prostatic disease European Journal of Cancer Supplements. 4: 159-160. DOI: 10.1016/S1359-6349(06)70531-6  0.481
2006 Carducci MA, Denmeade SR. Advances in the understanding and treatment of prostate cancer Advanced Studies in Medicine. 6.  0.503
2005 Aggarwal S, Janssen S, Wadkins RM, Harden JL, Denmeade SR. A combinatorial approach to the selective capture of circulating malignant epithelial cells by peptide ligands. Biomaterials. 26: 6077-86. PMID 15907998 DOI: 10.1016/J.Biomaterials.2005.03.040  0.569
2005 Singh P, Mhaka AM, Christensen SB, Gray JJ, Denmeade SR, Isaacs JT. Applying linear interaction energy method for rational design of noncompetitive allosteric inhibitors of the sarco- and endoplasmic reticulum calcium-ATPase. Journal of Medicinal Chemistry. 48: 3005-14. PMID 15828839 DOI: 10.1021/Jm049319A  0.759
2005 Denmeade SR, Isaacs JT. The SERCA pump as a therapeutic target: making a "smart bomb" for prostate cancer. Cancer Biology & Therapy. 4: 14-22. PMID 15662118 DOI: 10.4161/Cbt.4.1.1505  0.655
2005 Bajaj GK, Garrett-Mayer E, Drew R, Sinibaldi VJ, Gaver M, Pili R, Denmeade S, Carducci MA, Eisenberger M, Deweese TL. A phase II study of imatinib mesylate in prostate cancer patients with evidence of biochemical relapse following definitive radical retropubic prostatectomy or radiation therapy Journal of Clinical Oncology. 23: 3092-3092. DOI: 10.1200/jco.2005.23.16_suppl.3092  0.422
2005 Bajaj G, Garret-Mayer E, Zhang Z, Drew R, Sinibaldi V, Gaver M, Pili R, Denmeade S, Carducci M, Nelson W, Eisenberger M, DeWeese T. A Phase II Study of Imatinib Mesylate in Prostate Cancer Patients With Evidence of Biochemical Relapse Following Definitive Radical Retropubic Prostatectomy or Radiation Therapy International Journal of Radiation Oncology*Biology*Physics. 63: S312. DOI: 10.1016/J.Ijrobp.2005.07.535  0.422
2004 Janssen S, Jakobsen CM, Rosen DM, Ricklis RM, Reineke U, Christensen SB, Lilja H, Denmeade SR. Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer. Molecular Cancer Therapeutics. 3: 1439-50. PMID 15542783  0.487
2004 Mhaka A, Gady AM, Rosen DM, Lo KM, Gillies SD, Denmeade SR. Use of methotrexate-based peptide substrates to characterize the substrate specificity of prostate-specific membrane antigen (PSMA). Cancer Biology & Therapy. 3: 551-8. PMID 15044850 DOI: 10.4161/Cbt.3.6.846  0.847
2004 Denmeade SR, Isaacs JT. The role of prostate-specific antigen in the clinical evaluation of prostatic disease. Bju International. 93: 10-5. PMID 15009080 DOI: 10.1111/J.1464-410X.2003.04634.X  0.563
2004 Lapidus RG, Dang W, Rosen DM, Gady AM, Zabelinka Y, O'Meally R, DeWeese TL, Denmeade SR. Anti-tumor effect of combination therapy with intratumoral controlled-release paclitaxel (PACLIMER microspheres) and radiation. The Prostate. 58: 291-8. PMID 14743469 DOI: 10.1002/Pros.10331  0.464
2004 Denmeade SR, Isaacs JT. Development of prostate cancer treatment: the good news. The Prostate. 58: 211-24. PMID 14743459 DOI: 10.1002/Pros.10360  0.613
2003 Denmeade SR, Jakobsen CM, Janssen S, Khan SR, Garrett ES, Lilja H, Christensen SB, Isaacs JT. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. Journal of the National Cancer Institute. 95: 990-1000. PMID 12837835 DOI: 10.1093/Jnci/95.13.990  0.639
2003 Denmeade SR, Litvinov I, Sokoll LJ, Lilja H, Isaacs JT. Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo. The Prostate. 56: 45-53. PMID 12746846 DOI: 10.1002/Pros.10213  0.633
2003 Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. The Prostate. 54: 249-57. PMID 12539223 DOI: 10.1002/Pros.10199  0.601
2002 Mhaka A, Denmeade SR, Yao W, Isaacs JT, Khan SR. A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer. Bioorganic & Medicinal Chemistry Letters. 12: 2459-61. PMID 12161157 DOI: 10.1016/S0960-894X(02)00433-X  0.862
2002 Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nature Reviews. Cancer. 2: 389-96. PMID 12044015 DOI: 10.1038/Nrc801  0.6
2002 Pinski J, Weeraratna A, Uzgare AR, Arnold JT, Denmeade SR, Isaacs JT. Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblasts. Cancer Research. 62: 986-9. PMID 11861369  0.406
2001 Jakobsen CM, Denmeade SR, Isaacs JT, Gady A, Olsen CE, Christensen SB. Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells. Journal of Medicinal Chemistry. 44: 4696-703. PMID 11741487 DOI: 10.1021/Jm010985A  0.521
2001 Weeraratna AT, Dalrymple SL, Lamb JC, Denmeade SR, Miknyoczki S, Dionne CA, Isaacs JT. Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 7: 2237-45. PMID 11489797  0.527
2001 Denmeade SR, Lövgren J, Khan SR, Lilja H, Isaacs JT. Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing. The Prostate. 48: 122-6. PMID 11433422 DOI: 10.1002/Pros.1088  0.517
2001 Denmeade SR, Sokoll LJ, Chan DW, Khan SR, Isaacs JT. Rapid communication: Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models Prostate. 48: 1-6. PMID 11391681 DOI: 10.1002/Pros.1075  0.628
2001 Denmeade SR, Tombal B, Isaacs JT. Apoptotic pathways in prostate cancer Advances in Cell Aging and Gerontology. 6: 23-54. DOI: 10.1016/S1566-3124(01)06002-3  0.462
2000 Gala JL, Loric S, Guiot Y, Denmeade SR, Gady A, Brasseur F, Heusterspreute M, Eschwege P, De Nayer P, Van Cangh P, Tombal B. Expression of Prostate-specific membrane antigen in transitional cell carcinoma of the bladder: Prognostic value? Clinical Cancer Research. 6: 4049-4054. PMID 11051255  0.303
2000 Khan SR, Denmeade SR. In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts Prostate. 45: 80-83. PMID 10960846 DOI: 10.1002/1097-0045(20000915)45:1<80::Aid-Pros10>3.0.Co;2-Q  0.62
2000 Tombal B, Weeraratna AT, Denmeade SR, Isaacs JT. Thapsigargin induces a calmodulin/calcineurin-dependent apoptotic cascade responsible for the death of prostatic cancer cells Prostate. 43: 303-317. PMID 10861750 DOI: 10.1002/1097-0045(20000601)43:4<303::Aid-Pros10>3.0.Co;2-V  0.466
2000 Laufer M, Denmeade SR, Sinibaldi VJ, Carducci MA, Eisenberger MA. Complete androgen blockade for prostate cancer: What went wrong? Journal of Urology. 164: 3-9. PMID 10840412 DOI: 10.1016/S0022-5347(05)67436-8  0.454
1999 Denmeade SR, Lin XS, Tombal B, Isaacs JT. Inhibition of caspase activity does not prevent the signaling phase of apoptosis in prostate cancer cells. The Prostate. 39: 269-79. PMID 10344216 DOI: 10.1002/(Sici)1097-0045(19990601)39:4<269::Aid-Pros7>3.0.Co;2-F  0.471
1999 Gao AC, Lou W, Ichikawa T, Denmeade SR, Barrett C, Isaacs JT. Suppression of the tumorigenicity of prostatic cancer cells by gene(s) located on human chromosome 19p13.1-13.2 Prostate. 38: 46-54. PMID 9973109 DOI: 10.1002/(Sici)1097-0045(19990101)38:1<46::Aid-Pros6>3.0.Co;2-9  0.528
1999 Denmeade SR. Apoptotic pathways in normal prostate and prostate cancers Prostate Journal. 1: 120-125. DOI: 10.1046/J.1525-1411.1999.09921.X  0.609
1998 Denmeade SR, Nagy A, Gao J, Lilja H, Schally AV, Isaacs JT. Enzymatic activation of a doxorubicin-peptide prodrug by prostate- specific antigen Cancer Research. 58: 2537-2540. PMID 9635575  0.566
1998 Denmeade SR, Isaacs JT. Enzymatic activation of prodrugs by prostate-specific antigen: Targeted therapy for metastatic prostate cancer Cancer Journal From Scientific American. 4: S15-S21. PMID 9619266  0.565
1997 Joseph IB, Nelson JB, Denmeade SR, Isaacs JT. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 3: 2507-11. PMID 9815654  0.492
1997 Lin XS, Denmeade SR, Cisek L, Isaacs JT. Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic cancer cells induced by thapsigargin. The Prostate. 33: 201-7. PMID 9365549 DOI: 10.1002/(Sici)1097-0045(19971101)33:3<201::Aid-Pros9>3.0.Co;2-L  0.508
1997 Denmeade SR, Lou W, Lövgren J, Malm J, Lilja H, Isaacs JT. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen Cancer Research. 57: 4924-4930. PMID 9354459  0.531
1997 Denmeade SR, McCloskey DE, Joseph IBJK, Hahm HA, Isaacs JT, Davidson NE. Apoptosis in Hormone-Responsive Malignancies Advances in Pharmacology. 41: 553-583. PMID 9204159 DOI: 10.1016/S1054-3589(08)61072-8  0.528
1997 Denmeade SR, Isaacs JT. Prostate cancer: Where are we and where are we going? British Journal of Urology, Supplement. 79: 2-7. PMID 9088266 DOI: 10.1111/J.1464-410X.1997.Tb00794.X  0.613
1996 Denmeade SR, Isaacs JT. Activation of Programmed (Apoptotic) Cell Death for the Treatment of Prostate Cancer Advances in Pharmacology. 35: 281-306. PMID 8920208 DOI: 10.1016/S1054-3589(08)60278-1  0.621
1996 Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. The Prostate. 28: 251-65. PMID 8602401 DOI: 10.1002/(Sici)1097-0045(199604)28:4<251::Aid-Pros6>3.0.Co;2-G  0.534
1996 Denmeade SR, Isaacs JT. Programmed cell death (apoptosis) and cancer chemotherapy Cancer Control. 3: 303-309. DOI: 10.1177/107327489600300401  0.306
Show low-probability matches.